85 results on '"Waters, David D."'
Search Results
2. Time to Recognize HIV Infection as a Major Cardiovascular Risk Factor.
- Author
-
Hsue, Priscilla Y. and Waters, David D.
- Subjects
- *
CARDIOVASCULAR diseases , *HYPERCHOLESTEREMIA , *HIV , *ATHEROSCLEROSIS , *HIV infections - Abstract
An introduction is presented in which editor discusses the articles within the issue on topics including cardiovascular diseases, HIV, and Hypercholesterolemia.
- Published
- 2018
- Full Text
- View/download PDF
3. Effect of Change in Body Weight on Incident Diabetes Mellitus in Patients With Stable Coronary Artery Disease Treated With Atorvastatin (from the Treating to New Targets Study)
- Author
-
Ong, Kwok-Leung, Waters, David D, Messig, Michael, Demicco, David A, Rye, Kerry-Anne, and Barter, Philip J
- Published
- 2014
- Full Text
- View/download PDF
4. Effect of Change in Body Weight on Incident Diabetes Mellitus in Patients With Stable Coronary Artery Disease Treated With Atorvastatin (from the Treating to New Targets Study).
- Author
-
Kwok-Leung Ong, Waters, David D., Messig, Michael, DeMicco, David A., Rye, Kerry-Anne, and Barter, Philip J.
- Subjects
- *
BODY weight , *DIABETES , *ATORVASTATIN , *METABOLIC syndrome risk factors , *STATINS (Cardiovascular agents) , *CORONARY disease - Abstract
Features of the metabolic syndrome are independent risk factors for new-onset diabetes mellitus (NODM) related to statin therapy. Obesity is the predominant underlying risk factor for the metabolic syndrome and diabetes mellitus. This study investigated whether change in body weight may predict NODM in statin-treated patients. A total of 7,595 patients without prevalent diabetes mellitus at baseline from the Treating to New Targets (TNT) study were included in this analysis. They were randomized to atorvastatin 10 or 80 mg/day and monitored for a median of 4.9 years. NODM developed in 659 patients (8.1% in the 10-mg group and 9.2% in the 80-mg group). There was a significant increase in body weight (0.9 kg, p <0.01 in both men and women) over 1 year after randomization. The increase in body weight was greater in patients with NODM than those without NODM (1.6 vs 0.9 kg, p <0.001). The association of change in body weight with NODM risk remained significant after adjusting for confounding factors (hazard ratios 1.33, 1.42, and 1.88 for quartiles 2, 3, and 4 compared with quartile 1, respectively). Similar results were obtained in patients with normal fasting glucose level. In conclusion, 1-year change in body weight is predictive of NODM in patients who underwent statin therapy from the TNT trial. Our study highlights the importance of weight control as a lifestyle measure to prevent statin-related NODM. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
5. Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy: Effect of Baseline Risk Factors for Diabetes
- Author
-
Waters, David D., Ho, Jennifer E., Boekholdt, S. Matthijs, DeMicco, David A., Kastelein, John J.P., Messig, Michael, Breazna, Andrei, and Pedersen, Terje R.
- Subjects
- *
ATORVASTATIN , *DIABETES risk factors , *CARDIOVASCULAR diseases , *BLOOD sugar , *TRIGLYCERIDES , *BODY mass index , *MYOCARDIAL infarction - Abstract
Objectives: The purpose of this study was to compare the incidence of new-onset diabetes (NOD) with cardiovascular (CV) event reduction at different levels of NOD risk. Background: Statins reduce the number of CV events but increase the incidence of NOD. We previously reported that 4 factors independently predicted NOD: fasting blood glucose >100 mg/dl, fasting triglycerides >150 mg/dl, body mass index >30 kg/m2, and history of hypertension. Methods: We compared NOD incidence with CV event reduction among 15,056 patients with coronary disease but without diabetes at baseline in the TNT (Treating to New Targets) (n = 7,595) and IDEAL (Incremental Decrease in Endpoints Through Aggressive Lipid Lowering) (n = 7,461) trials. CV events included coronary heart disease death, myocardial infarction, stroke, and resuscitated cardiac arrest. Results: Among 8,825 patients with 0 to 1 of the aforementioned NOD risk factors at baseline, NOD developed in 142 of 4,407 patients in the atorvastatin 80 mg group and in 148 of 4,418 in the atorvastatin 10 mg and simvastatin 20 to 40 mg groups (3.22% vs. 3.35%; hazard ratio [HR]: 0.97; 95% confidence intervals [CI]: 0.77 to 1.22). Among the remaining 6,231 patients with 2 to 4 NOD risk factors, NOD developed in 448 of 3,128 in the atorvastatin 80 mg group and in 368 of 3,103 in the lower-dose groups (14.3% vs. 11.9%; HR: 1.24; 95% CI: 1.08 to 1.42; p = 0.0027). The number of CV events was significantly reduced with atorvastatin 80 mg in both NOD risk groups. Conclusions: Compared with lower-dose statin therapy, atorvastatin 80 mg/day did not increase the incidence of NOD in patients with 0 to 1 NOD risk factors but did, by 24%, among patients with 2 to 4 NOD risk factors. The number of CV events was significantly reduced with atorvastatin 80 mg in both NOD risk groups. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
6. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2
- Author
-
Santos, Raul D., Waters, David D., Tarasenko, Lisa, Messig, Michael, Jukema, J. Wouter, Chiang, Cheng-Wen, Ferrieres, Jean, and Foody, JoAnne M.
- Subjects
- *
DYSLIPIDEMIA , *HIGH density lipoproteins , *LOW density lipoproteins , *TRIGLYCERIDES , *CORONARY heart disease risk factors , *MEDICAL statistics , *COMPARATIVE studies , *THERAPEUTICS - Abstract
Abstract: Objective: This study evaluated the success in attaining non-HDL-cholesterol (non-HDL-C) goals in the multinational L-TAP 2 study. Methods: 9955 patients ≥20 years of age with dyslipidemia on stable lipid-lowering therapy were enrolled from nine countries. Results: Success rates for non-HDL-C goals were 86% in low, 70% in moderate, and 52% in high-risk patients (63% overall). In patients with triglycerides of >200 mg/dL success rates for non-HDL-C goals were 35% vs. 69% in those with ≤200 mg/dL (p < 0.0001). Among patients attaining their LDL-C goal, 18% did not attain their non-HDL-C goal. In those with coronary disease and at least two risk factors, only 34% and 30% attained respectively their non-HDL-C and LDL-C goals. Rates of failure in attaining both LDL-C and non-HDL-C goals were highest in Latin America. Conclusions: Non-HDL-C goal attainment lagged behind LDL-C goal attainment; this gap was greatest in higher-risk patients. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
7. Relation of Improvement in Estimated Glomerular Filtration Rate With Atorvastatin to Reductions in Hospitalizations for Heart Failure (from the Treating to New Targets [TNT] Study)
- Author
-
Ho, Jennifer E., Waters, David D., Kean, Allison, Wilson, Daniel J., DeMicco, David A., Breazna, Andrei, Wun, Chuan-Chuan, Deedwania, Prakash C., and Khush, Kiran K.
- Subjects
- *
GLOMERULAR filtration rate , *ATORVASTATIN , *HOSPITAL care , *HEART failure , *KIDNEY diseases , *LOW density lipoproteins - Abstract
Impaired kidney function often accompanies heart failure (HF) and is associated with a worse prognosis. This post hoc analysis of the Treating to New Targets (TNT) trial examined whether the observed decrease in HF hospitalizations with high- compared to low-dose atorvastatin could be related to improvements in kidney function. Of 10,001 TNT participants, 9,376 had estimated glomerular filtration rate (eGFR) measurements at baseline and 1 year and were included in this analysis. The association of change in year-1 eGFR and subsequent HF hospitalization was examined using Cox regression models. In total 218 participants developed subsequent HF hospitalization. Little change in eGFR occurred over 1 year in the atorvastatin 10-mg group, whereas eGFR improved in the 80-mg group by 1.48 ml/min/1.73 m2 (95% confidence interval 1.29 to 1.67, p <0.0001). Subsequent HF was preceded by a decrease in eGFR over 1 year compared to modest improvement in those without subsequent HF (−0.09 ± 7.89 vs 0.81 ± 6.90 ml/min/1.73 m2, p = 0.0015). After adjusting for baseline eGFR, each 5-ml/min/1.73 m2 increase in eGFR at 1 year was associated with a lower risk of subsequent HF hospitalization (hazard ratio 0.85, 95% confidence interval 0.77 to 0.94, p = 0.002). This relation was independent of treatment effect or change in low-density lipoprotein cholesterol level at 1 year. In conclusion, treatment with high- compared to low-dose atorvastatin was associated with improvement in eGFR at 1 year, which was related to a decrease in subsequent HF hospitalization. This suggests that improvement in kidney function may be related to the beneficial effect of high-dose atorvastatin on HF hospitalization. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
8. Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin: Results From 3 Large Randomized Clinical Trials
- Author
-
Waters, David D., Ho, Jennifer E., DeMicco, David A., Breazna, Andrei, Arsenault, Benoit J., Wun, Chuan-Chuan, Kastelein, John J., Colhoun, Helen, and Barter, Philip
- Subjects
- *
DIABETES , *LOW density lipoproteins , *MYOCARDIAL infarction , *CHOLESTEROL , *STATINS (Cardiovascular agents) , *TYPE 2 diabetes , *BODY mass index , *CONFIDENCE intervals , *CLINICAL trials - Abstract
Objectives: We sought to examine the incidence and clinical predictors of new-onset type 2 diabetes mellitus (T2DM) within 3 large randomized trials with atorvastatin. Background: Statin therapy might modestly increase the risk of new-onset T2DM. Methods: We used a standard definition of diabetes and excluded patients with prevalent diabetes at baseline. We identified baseline predictors of new-onset T2DM and compared the event rates in patients with and without new-onset T2DM. Results: In the TNT (Treating to New Targets) trial, 351 of 3,798 patients randomized to 80 mg of atorvastatin and 308 of 3,797 randomized to 10 mg developed new-onset T2DM (9.24% vs. 8.11%, adjusted hazard ratio [HR]: 1.10, 95% confidence interval [CI]: 0.94 to 1.29, p = 0.226). In the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial, 239 of 3,737 patients randomized to atorvastatin 80 mg/day and 208 of 3,724 patients randomized to simvastatin 20 mg/day developed new-onset T2DM (6.40% vs. 5.59%, adjusted HR: 1.19, 95% CI: 0.98 to 1.43, p = 0.072). In the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial, new-onset T2DM developed in 166 of 1,905 patients randomized to atorvastatin 80 mg/day and in 115 of 1,898 patients in the placebo group (8.71% vs. 6.06%, adjusted HR: 1.37, 95% CI: 1.08 to 1.75, p = 0.011). In each of the 3 trials, baseline fasting blood glucose, body mass index, hypertension, and fasting triglycerides were independent predictors of new-onset T2DM. Across the 3 trials, major cardiovascular events occurred in 11.3% of patients with and 10.8% of patients without new-onset T2DM (adjusted HR: 1.02, 95% CI: 0.77 to 1.35, p = 0.69). Conclusions: High-dose atorvastatin treatment compared with placebo in the SPARCL trial is associated with a slightly increased risk of new-onset T2DM. Baseline fasting glucose level and features of the metabolic syndrome are predictive of new-onset T2DM across the 3 trials. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
9. Impact of Smoking on Cardiovascular Events in Patients With Coronary Disease Receiving Contemporary Medical Therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trials)
- Author
-
Frey, Paul, Waters, David D., DeMicco, David A., Breazna, Andrei, Samuels, Larry, Pipe, Andrew, Wun, Chuan-Chuan, and Benowitz, Neal L.
- Subjects
- *
SMOKING , *CORONARY disease , *MYOCARDIAL infarction , *CEREBROVASCULAR disease , *CIGARETTE smokers , *CLINICAL trials , *STATINS (Cardiovascular agents) , *PATIENTS - Abstract
To define the incremental risk of cigarette smoking in patients with coronary disease receiving contemporary medical therapy, we performed a post hoc analysis of 18,885 patients by combining data from the Treating to New Targets (TNT) and the Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) trials. These studies compared high-dose treatment (atorvastatin 80 mg/day) to moderate-dose treatment (atorvastatin 10 mg/day in TNT and simvastatin 20 to 40 mg/day in IDEAL) in patients with established coronary heart disease. The primary end point of this pooled analysis was major cardiovascular events, a composite of cardiac death, myocardial infarction, stroke, or resuscitated cardiac arrest. At baseline 4,196 patients had never smoked, 11,513 were ex-smokers, and 3,176 were current smokers. The adjusted hazard ratio for current smokers compared to never smokers was 1.68 (95% confidence interval 1.46 to 1.94) and that for current smokers compared to ex-smokers was 1.57 (95% confidence interval 1.41 to 1.76). Event rates for current smokers compared to ex-smokers were similarly increased in each treatment group. The difference in absolute event rates between current and ex-smokers in this pooled analysis was 4.5%, which is >2 times as large as the decrease in absolute event rates between high-dose and moderate-dose statin therapy found in the IDEAL (1.7%) and TNT (2.2%) trials, respectively. In conclusion, in patients with coronary disease receiving modern medical therapy, smoking cessation is of substantial benefit with a number needed to treat of 22 to prevent a major cardiovascular event over 5 years. Smoking cessation deserves greater emphasis in secondary prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
10. Early Statin Therapy in Acute Coronary Syndromes: The Successful Cycle of Evidence, Guidelines, and Implementation
- Author
-
Waters, David D. and Ku, Ivy
- Subjects
- *
STATINS (Cardiovascular agents) , *CORONARY heart disease treatment , *HOSPITAL admission & discharge , *MYOCARDIAL infarction , *PLACEBOS , *LOW density lipoproteins - Abstract
That statins should be prescribed for patients before hospital discharge after an episode of acute coronary syndrome (ACS) is a Level of Evidence: 1A recommendation of the American College of Cardiology/American Heart Association Joint Task Force. This level of recommendation is based upon 2 clinical trials: the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) and PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) trials. In the MIRACL trial, 3,086 patients with unstable angina or non–Q-wave myocardial infarction were randomized within 4 days of the event to atorvastatin 80 mg/day or to placebo and followed for 16 weeks. The primary composite end point occurred in 14.8% of atorvastatin patients and 17.4% of placebo patients, a 16% relative risk reduction (p = 0.048). In the PROVE-IT trial, 4,162 patients hospitalized with an ACS within the preceding 10 days were randomized to atorvastatin 80 mg/day or pravastatin 40 mg/day and were followed for a mean of 24 months. The primary event rate was 22.4% in the atorvastatin group and 26.3% in the pravastatin group, a 16% relative risk reduction (p = 0.005). A strong trend toward a reduction in total mortality was seen in the atorvastatin group (2.2% vs. 3.2%, p = 0.07). Using a composite end point of death, myocardial infarction, and rehospitalization for ACS, the difference between the treatment groups is already statistically significant at 30 days and remains so throughout the follow-up period. Comprehensive treatment programs in ACS patients that include initiation of statins before hospital discharge have been shown to improve outcomes such as recurrent myocardial infarction and total mortality at 1 year. Guidelines prove their utility when their implementation improves outcomes across a broad population at risk, such as in this instance. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
11. Comparison of Effectiveness of Atorvastatin 10 mg Versus 80 mg in Reducing Major Cardiovascular Events and Repeat Revascularization in Patients With Previous Percutaneous Coronary Intervention (Post Hoc Analysis of the Treating to New Targets [TNT] Study)
- Author
-
Johnson, Colleen, Waters, David D., DeMicco, David A., Breazna, Andrei, Bittner, Vera, Greten, Heiner, Grundy, Scott M., and LaRosa, John C.
- Subjects
- *
LOW density lipoproteins , *CORONARY disease , *MYOCARDIAL revascularization , *CORONARY artery bypass , *CONFIDENCE intervals - Abstract
The Treating to New Targets (TNT) study demonstrated that intensive atorvastatin therapy to achieve low-density lipoprotein cholesterol concentrations well below recommended target levels provides an incremental clinical benefit in patients with stable coronary artery disease. This post hoc analysis of the TNT study was conducted to investigate whether this benefit extends to patients with previous percutaneous coronary intervention (PCI). A total of 10,001 patients with clinically evident coronary artery disease, including 5,407 patients with previous PCI, were randomized to atorvastatin 10 or 80 mg/day and followed for a median of 4.9 years. The primary end point was the occurrence of a first major cardiovascular event. Revascularization, a component of a secondary end point, was also examined. In patients with previous PCI, mean low-density lipoprotein cholesterol levels at study end were 79.5 mg/dl in the 80-mg arm and 100.8 mg/dl in the 10-mg arm. First major cardiovascular events occurred in 230 patients (8.6%) receiving high-dose atorvastatin and 289 patients (10.6%) receiving low-dose atorvastatin (hazard ratio 0.79, 95% confidence interval 0.67 to 0.94, p = 0.008). Repeat revascularization during follow-up (PCI or coronary artery bypass grafting) was performed in 466 patients (17.3%) in the 80-mg arm and 624 patients (22.9%) in the 10-mg arm (hazard ratio 0.73, 95% confidence interval 0.65 to 0.82, p <0.0001). In conclusion, intensive lipid lowering to a mean low-density lipoprotein cholesterol level of 79.5 mg/dl (2.1 mmol/L) with atorvastatin 80 mg/day in patients with previous PCI reduces major cardiovascular events by 21% and repeat revascularizations by 27% compared with a less intensive lipid-lowering regimen. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
12. Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery
- Author
-
Shah, Sanjiv J., Waters, David D., Barter, Philip, Kastelein, John J.P., Shepherd, James, Wenger, Nanette K., DeMicco, David A., Breazna, Andrei, and LaRosa, John C.
- Subjects
- *
CORONARY disease , *MYOCARDIAL revascularization , *CORONARY artery bypass , *MYOCARDIAL infarction - Abstract
Objectives: The aim of this post hoc analysis from the TNT (Treating to New Targets) trial is to determine whether patients with previous coronary artery bypass grafting (CABG) surgery achieved clinical benefit from intensive low-density lipoprotein (LDL)-cholesterol lowering. Background: The development and progression of atherosclerosis is accelerated in coronary venous bypass grafts. Methods: A total of 10,001 patients with documented coronary disease, including 4,654 with previous CABG, were randomized to atorvastatin 80 or 10 mg/day and were followed for a median of 4.9 years. The primary end point was the occurrence of a first major cardiovascular event (cardiac death, nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke). Results: A first major cardiovascular event occurred in 11.4% of the patients with prior CABG and 8.5% of those without prior CABG (p < 0.001). In CABG patients, mean LDL-cholesterol levels at study end were 79 mg/dl in the 80-mg arm and 101 mg/dl in the 10-mg arm, and the primary event rate was 9.7% in the 80-mg arm and 13.0% in the 10-mg arm (hazard ratio 0.73, 95% confidence interval 0.62 to 0.87, p = 0.0004). Repeat revascularization during follow-up, either CABG or percutaneous coronary intervention, was performed in 11.3% of the CABG patients in the 80-mg arm and 15.9% in the 10-mg arm (hazard ratio 0.70, 95% confidence interval 0.60 to 0.82, p < 0.0001). Conclusions: Intensive LDL-cholesterol lowering to a mean of 79 mg/dl with atorvastatin 80 mg/day in patients with previous CABG reduces major cardiovascular events by 27% and the need for repeat coronary revascularization by 30%, compared with less intensive cholesterol-lowering to a mean of 101 mg/dl with atorvastatin 10 mg/day. (A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels [TNT]; NCT00327691) [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
13. Preventing and Treating Stroke and Transient Ischemic Attack
- Author
-
DeFaria Yeh, Doreen and Waters, David D.
- Published
- 2008
- Full Text
- View/download PDF
14. Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study
- Author
-
Waters, David D., LaRosa, John C., Barter, Philip, Fruchart, Jean-Charles, Gotto, Antonio M., Carter, Roddy, Breazna, Andrei, Kastelein, John J.P., and Grundy, Scott M.
- Subjects
- *
CEREBRAL ischemia , *CORONARY disease , *ISOPENTENOIDS , *MYOCARDIAL infarction - Abstract
Objective: We sought to assess the effects on cerebrovascular events of treating patients with stable coronary disease with low-density lipoprotein cholesterol (LDL-C) levels substantially below 100 mg/dl. Background: Lowering LDL-C with statins has been shown to reduce the risk of stroke in patients with stable coronary disease. In observational studies, naturally low cholesterol levels have been associated with an increased risk of hemorrhagic stroke. The cerebrovascular benefits of treating patients with stable coronary disease to LDL-C levels substantially below 100 mg/dl have not been previously investigated. Methods: We describe an analysis of cerebrovascular events in the Treating to New Targets study, a trial where 10,001 patients with documented coronary disease were randomized to treatment with atorvastatin at 10 mg/day or 80 mg/day and followed for a median of 4.9 years. Results: Mean LDL-C levels were 101 mg/dl on 10 mg atorvastatin and 77 mg/dl on 80 mg. In addition to the reduction in major cardiovascular events (hazard ratio 0.78, 95% confidence interval [CI] 0.69 to 0.89; p = 0.0002), the primary end point of the trial, patients in the 80-mg arm experienced a reduction in cerebrovascular events (hazard ratio 0.77, 95% CI 0.64 to 0.93; p = 0.007) and stroke (hazard ratio 0.75, 95% CI 0.59 to 0.96; p = 0.02). Each 1-mg/dl reduction in LDL-C with treatment was associated with a 0.6% relative risk reduction in cerebrovascular events (p = 0.002) and a 0.5% relative risk reduction in stroke (p = 0.041). The incidence of hemorrhagic stroke was similar in the 80-mg and 10-mg groups, 16 and 18 respectively, and the hemorrhagic strokes were distributed evenly across quintiles of achieved LDL-C during treatment. Conclusions: Among patients with established coronary disease, treating to an LDL-cholesterol substantially below 100 mg/dl with 80 mg/day atorvastatin reduces both stroke and cerebrovascular events by an additional 20% to 25% compared with the 10 mg/day dose. An increase in hemorrhagic stroke was not seen at low LDL-C levels. (Treating to New Targets; http://www.clinicaltrials.gov; NCT00327691). [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
15. What the Statin Trials Have Taught Us
- Author
-
Waters, David D.
- Subjects
- *
ATHEROSCLEROSIS , *CARDIOVASCULAR diseases , *STATINS (Cardiovascular agents) , *INFLAMMATION , *CLINICAL trials - Abstract
It has taken a century since Anitschkow began feeding cholesterol to rabbits to study the role of cholesterol in atherosclerosis to be fully appreciated and for the potential of cholesterol reduction to prevent cardiovascular events to be fully realized. The body of clinical trial data testing the effects of statins on coronary heart disease is extensive and convincing. A 1% reduction in low-density lipoprotein cholesterol reduces coronary events by approximately 1%. With large doses of potent statins, low-density lipoprotein cholesterol levels and coronary events can thus be reduced by approximately 50%. The anti-inflammatory effects of large doses of atorvastatin likely contribute to the early event reduction seen early after acute coronary syndromes. Translating this information into clinical practice presents a challenge: many patients who would benefit from statins remain untreated or undertreated or discontinue treatment soon after it is initiated. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
16. Safety of High-Dose Atorvastatin Therapy
- Author
-
Waters, David D.
- Subjects
- *
STATINS (Cardiovascular agents) , *MUSCLE diseases , *MYOCARDIAL revascularization , *CLINICAL trials - Abstract
This article reviews the safety of statins, with emphasis on high-dose atorvastatin (80 mg), the agent with the most efficacy data for clinical outcomes. Although elevated levels of hepatic enzymes were of concern when statins were first introduced, a review of data from large clinical trials shows that elevations in hepatic enzymes are rare and do not lead to clinically significant liver disease. Despite the withdrawal of cerivastatin because of fatal rhabdomyolysis, the risk of this complication with other statins is extremely low. Mild and often transient myalgia is more commonly reported. The safety of high-dose atorvastatin has been evaluated in >11,000 patients, and rates of clinically significant myopathy and elevated hepatic enzymes were extremely low. Simvastatin at doses up to 40 mg is also associated with low rates of elevated hepatic enzymes and myopathy. However, the 80-mg dose of simvastatin carries a risk of myopathy (muscle symptoms and creatine kinase levels >10,000 U/L) of approximately 1 in 250. The clinical benefits of preventing vascular events, myocardial infarction, stroke, and need for revascularization outweigh the low rates of adverse events associated with high-dose statin therapy in high- and intermediate-risk patients. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
17. Soluble fibrin, C-reactive protein, fibrinogen, factor VII, antithrombin, proteins C and S, tissue factor, d-dimer, and prothrombin fragment 1 + 2 in men with acute myocardial infarction ≤45 years of age
- Author
-
Saigo, Masahiko, Waters, David D., Abe, Satoshi, Biro, Sadatoshi, Minagoe, Shinichi, Maruyama, Ikuro, and Tei, Chuwa
- Subjects
- *
C-reactive protein , *FIBRINOGEN , *BLOOD coagulation factors , *BLOOD proteins - Abstract
To evaluate the contribution of hematologic factors and long-term inflammation to the development of myocardial infarction at a young age, we measured hematologic variables, including soluble fibrin and high-sensitivity C-reactive protein, in 90 patients who had myocardial infarction and 138 controls ≤45 years of age. Plasma levels of soluble fibrin and C-reactive protein were significantly higher in patients than in controls. On multivariate regression analysis, soluble fibrin was the strongest predictor of myocardial infarction at a young age. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
18. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?
- Author
-
Waters, David D., Guyton, John R., Herrington, David M., McGowan, Mary P., Wenger, Nanette K., Shear, Charles, and TNT Steering Committee Members and Investigators
- Subjects
- *
LIPOPROTEINS , *CHOLESTEROL , *MYOCARDIAL infarction , *DRUG dosage - Abstract
The Treating to New Targets (TNT) trial is a parallel-group study that has randomized 10,003 patients from 14 countries to double-blind treatment with either atorvastatin 10 or 80 mg. During the double-blind period, low-density lipoprotein (LDL) cholesterol levels are expected to reach approximate mean values of 100 mg/dl (2.6 mmol/L) for the low-dose atorvastatin group and 75 mg/dl (1.9 mmol/L) for the high-dose group. Randomized patients are expected to be followed for an average of 5 years. The primary end point is the time to occurrence of a major cardiovascular event, defined as coronary heart disease death, nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke. The large patient numbers in the TNT study and long follow-up should ensure that there is adequate power to definitively determine if reducing LDL cholesterol levels to approximately 75 mg/dl (1.9 mmol/L) can provide additional clinical benefit. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
19. Effects of Hormone Replacement Therapy and Antioxidant Vitamin Supplements on Coronary Atherosclerosis in Postmenopausal Women: A Randomized Controlled Trial.
- Author
-
Waters, David D., Alderman, Edwin L., Hsia, Judith, Howard, Barbara V., Cobb, Frederick R., Rogers, William J., Ouyang, Pamela, Thompson, Paul, Tardif, Jean Claude, Higginson, Lyall, Bittner, Vera, Steffes, Michael, Gordon, David J., Proschan, Michael, Younes, Naji, and Verter, Joel I.
- Subjects
- *
DISEASES in women , *HORMONE therapy for menopause , *CORONARY disease , *HEART diseases , *MEDICAL experimentation on humans , *CLINICAL medicine , *CORONARY artery stenosis , *PLACEBOS - Abstract
Context: Hormone replacement therapy (HRT) and antioxidant vitamins are widely used for secondary prevention in postmenopausal women with coronary disease, but no clinical trials have demonstrated benefit to support their use. Objective: To determine whether HRT or antioxidant vitamin supplements, alone or in combination, influence the progression of coronary artery disease in postmenopausal women, as measured by serial quantitative coronary angiography. Design, Setting, and Patients: The Women's Angiographic Vitamin and Estrogen (WAVE) Trial, a randomized, double-blind trial of 423 postmenopausal women with at least one 15% to 75% coronary stenosis at baseline coronary angiography. The trial was conducted from July 1997 to January 2002 in 7 clinical centers in the United States and Canada. Interventions: Patients were randomly assigned in a 2 × 2 factorial design to receive either 0.625 mg/d of conjugated equine estrogen (plus 2.5 mg/d of medroxyprogesterone acetate for women who had not had a hysterectomy), or matching placebo, and 400 IU of vitamin E twice daily plus 500 mg of vitamin C twice daily, or placebo. Main Outcome Measure: Annualized mean (SD) change in minimum lumen diameter (MLD) from baseline to concluding angiogram of all qualifying coronary lesions averaged for each patient. Patients with intercurrent death or myocardial infarction (MI) were imputed the worst rank of angiographic outcome. Results: The mean (SD) interval between angiograms was 2.8 (0.9) years. Coronary progression, measured in mean (SD) change, worsened with HRT by 0.047 (0.15) mm/y and by 0.024 (0.15) mm/y with HRT placebo (P = .17); and for antioxidant vitamins by 0.044 (0.15) mm/y and with vitamin placebo by 0.028 (0.15) mm/y (P = .32). When patients with intercurrent death or MI were included, the primary outcome showed an increased risk for women in the active HRT group (P = .045), and suggested an increased risk in the active vitamin group (P = .09). Fourteen... [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
20. Early pharmacologic intervention and plaque stability in acute coronary syndromes.
- Author
-
Waters, David D. and Waters, D D
- Subjects
- *
LOW density lipoproteins , *STATINS (Cardiovascular agents) , *CORONARY disease - Abstract
Remarkable therapeutic advances in the treatment of acute coronary syndromes (ACS) have been made with antiplatelet and antithrombotic therapy. However, these therapies alone do not appear to completely stabilize culprit lesions. Evidence from a variety of sources suggests that intensive cholesterol lowering with statins favorably influences culprit lesion stabilization in patients with ACS. Potential mechanisms of benefit include improvements in endothelial function, decreased propensity for platelet thrombus formation, and reduction in inflammation at the site of the lesion. The Myocardial Ischemia with Aggressive Cholesterol Lowering (MIRACL) study is the first large-scale clinical trial to examine whether these mechanisms translate into clinical-event reduction in patients with ACS as well as the substantial proved benefits in the chronic coronary syndromes. In this trial, early initiation of atorvastatin after an episode of unstable angina or non-Q-wave myocardial infarction reduced events over the ensuing 16 weeks. It is hoped that a growing awareness of the benefits of early statin therapy to stabilize culprit lesions in ACS will lead to an increase in the proportion of coronary patients who will receive this beneficial therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
21. What Is the Role of Intensive Cholesterol Lowering in the Treatment of Acute Coronary Syndromes?
- Author
-
Waters, David D. and Hsue, Priscilla Y.
- Subjects
- *
CHOLESTEROL , *HEART diseases , *THERAPEUTICS - Abstract
Examines the role of intensive cholesterol lowering in the treatment of acute coronary syndromes in the United States. Treatment with statins after an acute coronary event; Comparison between unstable and stable coronary disease; Treatment strategies in acute coronary syndromes.
- Published
- 2001
- Full Text
- View/download PDF
22. Are We Aggressive Enough in Lowering Cholesterol?
- Author
-
Waters, David D.
- Subjects
- *
STATINS (Cardiovascular agents) , *CARDIOVASCULAR diseases , *LOW density lipoproteins - Abstract
Assesses the efficacy of statin therapy in preventing cardiovascular risk. Statin trials for primary and secondary prevention of coronary artery disease; Effect of statin on low-density lipoprotein cholesterol levels; Treatment decision based on low-density lipoprotein cholesterol level.
- Published
- 2001
- Full Text
- View/download PDF
23. Short- and medium-term outcome differences in women and men after primary percutaneous transluminal mechanical revascularization for acute myocardial infarction.
- Author
-
Azar, Rabith R., Waters, David D., Azar, R R, Waters, D D, McKay, R G, Giri, S, Hirst, J A, Mitchell, J F, Fram, D B, and Kiernan, F J
- Subjects
- *
MYOCARDIAL infarction , *MYOCARDIAL revascularization , *THERAPEUTICS , *HEART diseases - Abstract
Women presenting with acute myocardial infarction (AMI) have a higher mortality with conventional medical and thrombolytic therapy when compared with men. The outcome after primary percutaneous transluminal mechanical revascularization has not yet been fully investigated. This study was performed to compare the characteristics and the short- and medium-term outcomes of women and men with AMI treated with primary percutaneous revascularization. A total of 182 consecutive patients (62 women and 120 men) were included. Baseline clinical characteristics were similar except that women were older than men, presented more often in cardiogenic shock, and had smaller reference vessel diameters. Stents and abciximab were used equally, but abciximab was stopped more often in women before completion of the 12-hour infusion because of higher bleeding rates. Acute procedural success rates were similar (92% and 97%) but mortality was much higher in women, both at 30-day follow-up (100% vs 0.9%; p <0.05) and during a mean follow-up of 6.9 +/- 4.1 months (15% vs 4.4%; p <0.05). Women also experienced more unfavorable cardiovascular events (recurrent unstable angina or AMI, target vessel revascularization) than men. However, after control for baseline clinical differences in a multivariate analysis, gender was not an independent predictor of survival, whereas age, cardiogenic shock, and completion of a 12-hour abciximab infusion were. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
24. Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL.
- Author
-
Kohli, Payal, Waters, David D, Nemr, Rita, Arsenault, Benoit J, Messig, Michael, DeMicco, David A, Laskey, Rachel, and Kastelein, John J P
- Published
- 2015
- Full Text
- View/download PDF
25. Risk of New-Onset Diabetes and Cardiovascular Risk Reduction From High-Dose Statin Therapy in Pre-Diabetics and Non–Pre-Diabetics: An Analysis From TNT and IDEAL.
- Author
-
Kohli, Payal, Waters, David D., Nemr, Rita, Arsenault, Benoit J., Messig, Michael, DeMicco, David A., Laskey, Rachel, and Kastelein, John J.P.
- Subjects
- *
CARDIOVASCULAR diseases risk factors , *PREDIABETIC state , *STATINS (Cardiovascular agents) , *DRUG dosage , *PLACEBOS , *DISEASE incidence , *CLINICAL trials - Published
- 2015
- Full Text
- View/download PDF
26. Estrogen therapy for unstable angina: Another bump for the bandwagon*<FN ID="FN1"><NO>*</NO>Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.</FN>
- Author
-
Waters, David D.
- Subjects
- *
DRUG therapy for angina pectoris , *CORONARY heart disease prevention , *ESTROGEN replacement therapy , *MEDROXYPROGESTERONE , *SYNTHETIC progestagens , *HORMONES , *THERAPEUTICS , *POSTMENOPAUSE - Published
- 2002
- Full Text
- View/download PDF
27. Management of a patient with angina pectoris.
- Author
-
Azar, Rabih R., Waters, David D., Azar, R R, and Waters, D D
- Subjects
- *
ANGINA pectoris , *CARDIAC catheterization , *CORONARY heart disease treatment , *COMBINED modality therapy , *CORONARY disease , *EXERCISE tests , *MYOCARDIAL revascularization , *SURGICAL stents , *TRANSLUMINAL angioplasty , *LIFESTYLES , *DIAGNOSIS ,ANGINA pectoris treatment - Abstract
Reports on the management of a 56-year-old patient with complaints of 'pressure' in the central chest with radiation into both arms. Presence of the symptom for approximately a year which was induced by exertion; Information obtained from the patient's cardiac catheterization with coronary cineangiography.
- Published
- 2001
- Full Text
- View/download PDF
28. Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
- Author
-
Roubille, François, Bouabdallaoui, Nadia, Kouz, Simon, Waters, David D., Diaz, Rafael, Maggioni, Aldo P., Pinto, Fausto J., Grégoire, Jean C., Gamra, Habib, Kiwan, Ghassan S., Berry, Colin, López-Sendón, José, Koenig, Wolfgang, Delorme, Laurent, Elbaz, Meyer, Coste, Pierre, Provencher, Mylène, Bassevitch, Zohar, Blondeau, Lucie, and L’Allier, Philippe L.
- Subjects
- *
TYPE 2 diabetes , *MYOCARDIAL infarction , *COLCHICINE , *CORONARY disease - Abstract
OBJECTIVE: The cardiovascular benefits of low-dose colchicine have been demonstrated in patients with coronary disease. Its effects were evaluated in this prespecified analysis in patients with type 2 diabetes (T2D) from the Colchicine Cardiovascular Outcomes Trial (COLCOT). RESEARCH DESIGN AND METHODS: COLCOT was a randomized, double-blinded trial of colchicine, 0.5 mg daily, versus placebo initiated within 30 days after a myocardial infarction. RESULTS: There were 959 patients with T2D enrolled and monitored for a median of 22.6 months. A primary end point event occurred in 8.7% of patients in the colchicine group and in 13.1% in the placebo group (hazard ratio 0.65; 95% CI 0.44–0.96; P = 0.03). Nausea was reported in 2.7% and 0.8% in the study groups (P = 0.03), and pneumonia occurred in 2.4% and 0.4% (P = 0.008). CONCLUSIONS: Among patients with T2D and a recent myocardial infarction, colchicine, 0.5 mg daily, leads to a large reduction of cardiovascular events. These results support the conduct of the COLCOT-T2D trial in primary prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. PCSK9 Inhibitors for Statin Intolerance?
- Author
-
Waters, David D., Hsue, Priscilla Y., and Bangalore, Sripal
- Subjects
- *
PROPROTEIN convertases , *STATINS (Cardiovascular agents) , *DRUG dosage , *MUSCLE diseases , *HEALTH outcome assessment - Abstract
The authors investigates the use of the PCSK9 inhibitor evolocumab in patients with statin intolerance related to muscle-related adverse effects. It mentions that a low statin dose can put a patient at risk for a cardiovascular event with intolerable muscle symptoms. It highlights long-term outcomes for early statin primary prevention trials.
- Published
- 2016
- Full Text
- View/download PDF
30. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
- Author
-
Tardif, Jean-Claude, Kouz, Simon, Waters, David D., Bertrand, Olivier F., Diaz, Rafael, Maggioni, Aldo P., Pinto, Fausto J., Ibrahim, Reda, Gamra, Habib, Kiwan, Ghassan S., Berry, Colin, López-Sendón, José, Ostadal, Petr, Koenig, Wolfgang, Angoulvant, Denis, Grégoire, Jean C., Lavoie, Marc-André, Dubé, Marie-Pierre, Rhainds, David, and Provencher, Mylène
- Subjects
- *
MYOCARDIAL infarction treatment , *ANGINA pectoris , *ANTI-inflammatory agents , *C-reactive protein , *CARDIOVASCULAR system , *CARDIOVASCULAR diseases , *COLCHICINE , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL care , *MEDICAL cooperation , *MYOCARDIAL infarction , *RESEARCH , *STROKE , *DISEASE relapse , *EVALUATION research , *RANDOMIZED controlled trials , *DISEASE incidence , *PROPORTIONAL hazards models , *BLIND experiment , *KAPLAN-Meier estimator ,CARDIOVASCULAR disease related mortality - Abstract
Background: Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis.Methods: We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end point was a composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. The components of the primary end point and safety were also assessed.Results: A total of 4745 patients were enrolled; 2366 patients were assigned to the colchicine group, and 2379 to the placebo group. Patients were followed for a median of 22.6 months. The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction, 0.26 (95% CI, 0.10 to 0.70) for stroke, and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization. Diarrhea was reported in 9.7% of the patients in the colchicine group and in 8.9% of those in the placebo group (P = 0.35). Pneumonia was reported as a serious adverse event in 0.9% of the patients in the colchicine group and in 0.4% of those in the placebo group (P = 0.03).Conclusions: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov number, NCT02551094.). [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
31. The curse of target lesion calcification: still active after all these years.
- Author
-
Waters, David D and Azar, Rabih R
- Published
- 2014
- Full Text
- View/download PDF
32. The Curse of Target Lesion Calcification: Still Active After All These Years ∗.
- Author
-
Waters, David D. and Azar, Rabih R.
- Published
- 2014
- Full Text
- View/download PDF
33. Meta-analyses of statin trials: clear benefit for primary prevention in the elderly.
- Author
-
Waters, David D
- Published
- 2013
- Full Text
- View/download PDF
34. Meta-Analyses of Statin Trials: Clear Benefit for Primary Prevention in the Elderly ∗.
- Author
-
Waters, David D.
- Published
- 2013
- Full Text
- View/download PDF
35. The SPARCL study: extending the indications of statin therapy for stroke?
- Author
-
Yeh, Doreen DeFaria and Waters, David D.
- Subjects
- *
STATINS (Cardiovascular agents) , *CEREBROVASCULAR disease , *TRANSIENT ischemic attack , *CORONARY disease , *CHOLESTEROL , *CARDIOVASCULAR agents - Abstract
BACKGROUND Treatment with statins has been reported to reduce the risk of stroke in patients with coronary heart disease (CHD). Whether patients without CHD who have suffered a previous stroke or transient ischemic attack (TIA) derive the same benefit from statin therapy has yet to be investigated. OBJECTIVE To establish whether daily atorvastatin reduces the risk of future stroke or TIA in patients without known CHD, but with a history of stroke or TIA. DESIGN From September 1998 to March 2001, the randomized, double-blind, placebo-controlled Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial enrolled men and women over the age of 18 years who had been diagnosed with stroke or TIA 1-6 months previously. All patients were mobile, had a modified Rankin score of 3 or less, and had an LDL cholesterol level of 2.59-4.92 mmol/I (100-190 mg/dl). None of the patients had evidence of CHD. Exclusion criteria included atrial fibrillation (AF) or other cardiac causes of embolism. INTERVENTION Lipid-lowering medication was withdrawn 30 days before screening, if applicable. Patients were then randomized to receive either 80 mg atorvastatin or placebo daily. Follow-up visits took place at 1,3, and 6 months from baseline and every 6 months thereafter; the final visits took place between March and June 2005. OUTCOME MEASURES The primary outcome was time from randomization to first stroke. Secondary outcomes, assessed individually and together as a composite, were stroke or TIA, cardiovascular events (major and minor), coronary events (major, minor and acute), and revascularization. Death from any cause was analyzed as a separate secondary outcome, but not as part of the composite. RESULTS Eligible patients were randomized to atorvastatin (n=2,365) or placebo (n=2,366). Baseline LDL cholesterol levels were not significantly different between the two groups (3.44±0.01 mmol/I [132.7±0.5mg/dl] and 3.46±0.01mmol/I [133.7±0.5mg/dl], respectively). During the course of the trial, the mean LDL cholesterol level decreased by 45% (to 1.89 ± 0.01 mmol/I [72.9 ± 0.5 mg/dl]) in patients receiving atorvastatin, compared with only a slight decrease (to 3.33 ± 0.01 mmol/I [128.5± 0.5mg/dl]) in the placebo group (P<0.001). After a median follow-up of 4.9 years (range 4.0-6.6 years), there were significantly more occurrences of the primary outcome in patients receiving placebo than in those receiving atorvastatin (311 versus 265; P=0.05). For atorvastatin compared with placebo, the 5-year absolute reductions in risk of stroke and major cardiovascular events were 2.2% (hazard ratio [HR] 0.84; 95% CI 0.71-0.99; P= 0.03) and 3.5% (HR 0.80, 95% CI 0.69-0.92; P=0.002), respectively. Notably, however, atorvastatin was associated with an increase in risk of hemorrhagic stroke (HR 1.66, 95% CI 1.08-2.55). There were no significant differences in mortality or incidence of treatment-related adverse events between the two groups. CONCLUSION In patients with a recent history of stroke or TIA and no known CHD, 80mg/day atorvastatin significantly reduces the risk of future stroke and cardiovascular events. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
36. Reassessment of National Cholesterol Education Program Adult Treatment Panel-III guidelines: one year later
- Author
-
Ansell, Benjamin J. and Waters, David D.
- Published
- 2002
- Full Text
- View/download PDF
37. Reply
- Author
-
Waters, David D., Boekholdt, S. Matthijs, and Pedersen, Terje R.
- Published
- 2013
- Full Text
- View/download PDF
38. IMPROVEMENT IN EGFR WITH ATORVASTATIN MAY CONTRIBUTE TO REDUCTIONS IN HOSPITALIZATIONS FOR CONGESTIVE HEART FAILURE: TREATING TO NEW TARGETS (TNT) STUDY
- Author
-
Kean, Allison, Waters, David D., Deedwania, Prakash C., Breazna, Andrei, DeMicco, David A., and Wilson, Daniel J.
- Published
- 2011
- Full Text
- View/download PDF
39. OLDER IS WISER: LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOAL ATTAINMENT IN A MULTINATIONAL SURVEY OF DYSLIPIDEMIC PATIENTS: A LIPID TREATMENT ASSESSMENT PROJECT (L-TAP) 2 SUBSTUDY
- Author
-
Santos, Raul D., Waters, David D., Ferrieres, Jean, Jukema, J-Wouter, Chiang, Cheng-Wen, Messig, Michael, and Tarasenko, Lisa
- Published
- 2010
- Full Text
- View/download PDF
40. Hemodynamic and Arrhythmogenic Effects of Cocaine in Hypertensive Individuals.
- Author
-
Secemsky, Eric, Lange, David, Waters, David D., Goldschlager, Nora F., and Hsue, Priscilla Y.
- Abstract
J Clin Hypertens (Greenwich). 2011;13:744-749. ©2011 Wiley Periodicals, Inc. Despite the increased risk of myocardial infarction, aortic dissection, and arrhythmias in patients with hypertension who use cocaine, the hemodynamic and arrhythmogenic effects of cocaine use have not been well characterized in this population. The authors hypothesized that patients with hypertension demonstrate extreme, transient changes in arterial pressures as well as new arrhythmic activity during cocaine use. Ambulatory blood pressures, heart rates, and electrocardiograms (AECGs) were recorded for 48 hours in 10 patients with a history of hypertension who smoke cocaine. Active cocaine use was identified through patient diaries and manual activation of the blood pressure cuff. Of the 10 patients studied (6 men, 7 African Americans, age 49±8 years), 8 were taking antihypertensive medications. The mean blood pressure prior to cocaine use was 126/77 mm Hg and average increase in systolic, diastolic, and mean arterial pressure after use was 74 mm Hg, 30 mm Hg, and 45 mm Hg, respectively ( P<.0001 for all). There was no significant change in heart rate. AECGs demonstrated arrhythmic activity during cocaine use, including 6 patients with increased atrial and ventricular ectopy, 2 patients with episodes of nonsustained atrial tachycardia, and 1 patient with 3 episodes of nonsustained monomorphic ventricular tachycardia. Cocaine use resulted in extreme elevations in arterial pressures in patients with hypertension taking medication. Cocaine use was also associated with an increase in arrhythmic activity. These findings may underlie the heightened risk of myocardial infarction, aortic dissection, and potentially lethal arrhythmias in patients with hypertension who use cocaine. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
41. Reaching C-Reactive Protein and Low-Density Lipoprotein Cholesterol Goals in Dyslipidemic Patients (from the Lipid Treatment Assessment Project [L-TAP] 2)
- Author
-
Chiang, Cheng-Wen, Santos, Raul D., Waters, David D., Messig, Michael, Tarasenko, Lisa, Jukema, J. Wouter, Ferrières, Jean, Foody, JoAnne, and Seung, Ki-Bae
- Subjects
- *
C-reactive protein , *LOW density lipoproteins , *CHOLESTEROL , *LIPIDS , *SMOKING cessation , *HEALTH outcome assessment - Abstract
The purpose of the present substudy of the Lipid Treatment Assessment Project 2 was to assess dual C-reactive protein (CRP) and low-density lipoprotein (LDL) cholesterol goal attainment across a spectrum of low-, moderate-, and high-risk patients with dyslipidemia in 8 countries in North America, Latin America, Europe, and Asia. Of the 9,518 patients studied overall, 45% were women, 64% had hypertension, 31% had diabetes, 14% were current smokers, 60% were high risk, and 79% were taking a statin. The median CRP level was 1.5 mg/L (interquartile range 0.2 to 2.8). On multivariate analysis, higher CRP levels were associated with older age, female gender, hypertension, current smoking, greater body mass index, larger waist circumference, LDL cholesterol level, and triglyceride/high-density lipoprotein cholesterol ratio. In contrast, being from Asia or taking a statin was associated with lower levels. Across all risk groups, 59% of patients attained the CRP target of <2 mg/L, and 33% had <1 mg/L. Overall, 44% of patients attained both their National Cholesterol Education Program Adult Treatment Panel III LDL cholesterol target and a CRP level of <2 mg/L, but only 26% attained their LDL cholesterol target and a CRP level of <1 mg/L. In the very high-risk group with coronary heart disease and ≥2 risk factors, only 19% attained both their LDL cholesterol goal and a CRP level of <2 mg/L and 12% their LDL cholesterol goal and a CRP level of <1 mg/L. In conclusion, with current treatment, most dyslipidemic patients do not reach the dual CRP and LDL cholesterol goals. Smoking cessation, weight reduction, and the greater use of more potent statins at higher doses might be able to improve these outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
42. Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial
- Author
-
Kelemen, Mark, Vaidya, Dhananjay, Waters, David D., Howard, Barbara V., Cobb, Frederick, Younes, Naji, Tripputti, Mark, and Ouyang, Pamela
- Subjects
- *
HORMONE therapy , *ANTIOXIDANTS , *VITAMINS , *CORONARY disease - Abstract
Abstract: We measured flow-mediated dilation (FMD) by high-resolution brachial ultrasound in 61 women who participated in the Women''s Angiographic Vitamin and Estrogen (WAVE) trial, a randomized controlled trial. There were no significant differences in the baseline demographics of women receiving hormone therapy (0.625mg/day of conjugated equine estrogen plus 2.5mg of medroxyprogesterone acetate for women who had not had a hysterectomy) or placebo; or vitamins (400 IU of Vitamin E and 500mg of Vitamin C twice daily) or placebo. Baseline FMD was impaired in all subjects (3.3±7.6%). Neither hormone therapy (4.1±5.2% at baseline, 4.2±5.0% at 3 months, and 4.1±6.5% at 34 months) nor antioxidant vitamins (3.0±8.3% at baseline; 3.5±4.6% at 3 months; 3.1±7.6% at 34 months) improved FMD (all p-values=NS). Endothelium-independent vasodilation, induced by nitroglycerin (NTG) was similar at baseline and was not affected by either therapy. In univariate and multivariate analysis, neither hormone therapy nor antioxidant vitamins were associated with FMD. Women with established coronary artery disease have impaired flow-mediated vasodilation of the brachial artery that does not improve after 3 months or up to 34 months of treatment with postmenopausal hormone therapy or antioxidant vitamins. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
43. Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons.
- Author
-
Chaitman, Bernard R., Hochman, Judith S., Alexander, Karen P., Berger, Jeffrey S., Reynolds, Harmony R., Bangalore, Sripal, Boden, William E., Lopes, Renato D., Demkow, Marcin, Perna, Gian Piero, Riezebos, Robert K., McFalls, Edward O., Banerjee, Subhash, Bagai, Akshay, Gosselin, Gilbert, O'Brien, Sean M., Rockhold, Frank W., Waters, David D., Thygesen, Kristian A., and Stone, Gregg W.
- Subjects
- *
MYOCARDIAL infarction , *CORONARY artery bypass , *CORONARY disease , *PERCUTANEOUS coronary intervention , *DEATH rate , *MYOCARDIAL ischemia - Abstract
Background: In the ISCHEMIA trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches), an initial invasive strategy did not significantly reduce rates of cardiovascular events or all-cause mortality in comparison with a conservative strategy in patients with stable ischemic heart disease and moderate/severe myocardial ischemia. The most frequent component of composite cardiovascular end points was myocardial infarction (MI).Methods: ISCHEMIA prespecified that the primary and major secondary composite end points of the trial be analyzed using 2 MI definitions. For procedural MI, the primary MI definition used creatine kinase-MB as the preferred biomarker, whereas the secondary definition used cardiac troponin. Procedural thresholds were >5 times the upper reference level for percutaneous coronary intervention and >10 times for coronary artery bypass grafting. Procedural MI definitions included (1) a category of elevated biomarker only events with much higher biomarker thresholds, (2) new ST-segment depression of ≥1 mm for the primary and ≥0.5 mm for the secondary definition, and (3) new coronary dissections >National Heart, Lung, and Blood Institute grade 3. We compared MI type, frequency, and prognosis by treatment assignment using both MI definitions.Results: Procedural MIs accounted for 20.1% of all MI events with the primary definition and 40.6% of all MI events with the secondary definition. Four-year MI rates in patients undergoing revascularization were more frequent with the invasive versus conservative strategy using the primary (2.7% versus 1.1%; adjusted hazard ratio [HR], 2.98 [95% CI, 1.87-4.73]) and secondary (8.2% versus 2.0%; adjusted HR, 5.04 [95% CI, 3.64-6.97]) MI definitions. Type 1 MIs were less frequent with the invasive versus conservative strategy using the primary (3.40% versus 6.89%; adjusted HR, 0.53 [95% CI, 0.41-0.69]; P<0.0001) and secondary (3.48% versus 6.89%; adjusted HR, 0.53 [95% CI, 0.41-0.69]; P<0.0001) definitions. The risk of subsequent cardiovascular death was higher after a type 1 MI than after no MI using the primary (adjusted HR, 3.38 [95% CI, 2.03-5.61]; P<0.001) or secondary MI definition (adjusted HR, 3.52 [2.11-5.88]; P<0.001).Conclusions: In ISCHEMIA, type 1 MI events using the primary and secondary definitions during 5-year follow-up were more frequent with an initial conservative strategy and associated with subsequent cardiovascular death. Procedural MI rates were greater in the invasive strategy and with the use of the secondary MI definition. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01471522. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
44. RE: Praluent (Alirocumab)-Induced Renal Injury.
- Author
-
Rosenson, Robert S., Larrey, Dominique, Waters, David D., and Olsson, Anders G.
- Subjects
- *
ACUTE kidney failure , *CREATINE kinase , *CREATININE , *MONOCLONAL antibodies , *NEPHROTOXICOLOGY , *RHABDOMYOLYSIS , *ROSUVASTATIN - Published
- 2018
- Full Text
- View/download PDF
45. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
- Author
-
Vallejo-Vaz, Antonio J, Fayyad, Rana, Boekholdt, S Matthijs, Hovingh, G Kees, Kastelein, John J, Melamed, Shari, Barter, Philip, Waters, David D, and Ray, Kausik K
- Abstract
Background: Mendelian randomization data suggest that the genetic determinants of lifetime higher triglyceride-rich lipoprotein-cholesterol (TRL-C) are causally related to cardiovascular disease and therefore a potential therapeutic target. The relevance of TRL-C among patients receiving statins is unknown. We assessed the relationship between TRL-C and cardiovascular risk, and whether this risk was modifiable among patients receiving statins in the TNT trial (Treating to New Targets).Methods: Patients with coronary heart disease and low-density lipoprotein cholesterol (LDL-C) 130 to 250 mg/dL entered an 8-week run-in phase with atorvastatin 10 mg/d (ATV10). After this period, participants with LDL-C <130 mg/dL entered the randomized phase with ATV10 (n=5006) versus atorvastatin 80 mg/d (ATV80, n=4995). The primary end point was coronary heart disease death, nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke (major adverse cardiovascular events [MACE]). TRL-C was calculated as total cholesterol minus high-density lipoprotein cholesterol minus LDL-C. The effect of atorvastatin on TRL-C was assessed during the run-in phase (ATV10) and randomized phase (ATV80 versus ATV10). The risk of MACE was assessed across quintiles (Q) of baseline TRL-C (and, for comparison, by baseline triglycerides and non-high-density lipoprotein cholesterol) during the randomized period. Last, the association between TRL-C changes with atorvastatin and cardiovascular risk was assessed by multivariate Cox regression.Results: ATV10 reduced TRL-C 10.7% from an initial TRL-C of 33.9±16.6 mg/dL. ATV80 led to an additional 15.4% reduction. Cardiovascular risk factors positively correlated with TRL-C. Among patients receiving ATV10, higher TRL-C was associated with higher 5-year MACE rates (Q1=9.7%, Q5=13.8%; hazard ratio Q5-versus-Q1, 1.48; 95% confidence interval, 1.15-1.92; P-trend<0.0001). ATV80 (versus ATV10) did not significantly alter the risk of MACE in Q1-Q2, but significantly reduced risk in Q3-Q5 (relative risk reduction, 29%-41%; all P<0.0250), with evidence of effect modification ( P-homogeneity=0.0053); results were consistent for triglycerides ( P-homogeneity=0.0101) and directionally similar for non-high-density lipoprotein cholesterol ( P-homogeneity=0.1387). Last, in adjusted analyses, a 1 SD percentage reduction in TRL-C with atorvastatin resulted in a significant lower risk of MACE (hazard ratio, 0.93; 95% confidence interval, 0.86-1.00; P=0.0482) independent of the reduction in LDL-C and of similar magnitude to that per 1 SD lowering in LDL-C (hazard ratio, 0.89; 95% confidence interval, 0.83-0.95; P=0.0008).Conclusions: The present post hoc analysis from TNT shows that increased TRL-C levels are associated with an increased cardiovascular risk and provides evidence for the cardiovascular benefit of lipid lowering with statins among patients who have coronary heart disease with high TRL-C.Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00327691. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
46. Body-Weight Fluctuations and Outcomes in Coronary Disease.
- Author
-
Bangalore, Sripal, Fayyad, Rana, Laskey, Rachel, DeMicco, David A., Messerli, Franz H., and Waters, David D.
- Abstract
Background: Body-weight fluctuation is a risk factor for death and coronary events in patients without cardiovascular disease. It is not known whether variability in body weight affects outcomes in patients with coronary artery disease.Methods: We determined intraindividual fluctuations in body weight from baseline weight and follow-up visits and performed a post hoc analysis of the Treating to New Targets trial, which involved assessment of the efficacy and safety of lowering low-density lipoprotein cholesterol levels with atorvastatin. The primary outcome was any coronary event (a composite of death from coronary heart disease, nonfatal myocardial infarction, resuscitated cardiac arrest, revascularization, or angina). Secondary outcomes were any cardiovascular event (a composite of any coronary event, a cerebrovascular event, peripheral vascular disease, or heart failure), death, myocardial infarction, or stroke.Results: Among 9509 participants, after adjustment for risk factors, baseline lipid levels, mean body weight, and weight change, each increase of 1 SD in body-weight variability (measured according to average successive variability and used as a time-dependent covariate) was associated with an increase in the risk of any coronary event (2091 events; hazard ratio, 1.04; 95% confidence interval [CI], 1.01 to 1.07; P=0.01), any cardiovascular event (2727 events; hazard ratio, 1.04; 95% CI, 1.02 to 1.07; P<0.001), and death (487 events; hazard ratio,1.09; 95% CI, 1.07 to 1.12; P<0.001). Among patients in the quintile with the highest variation in body weight, the risk of a coronary event was 64% higher, the risk of a cardiovascular event 85% higher, death 124% higher, myocardial infarction 117% higher, and stroke 136% higher than it was among those in the quintile with the lowest variation in body weight in adjusted models.Conclusions: Among participants with coronary artery disease, fluctuation in body weight was associated with higher mortality and a higher rate of cardiovascular events independent of traditional cardiovascular risk factors. (Funded by Pfizer; ClinicalTrials.gov number, NCT00327691 .). [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
47. 2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?
- Author
-
Bangalore, Sripal, Fayyad, Rana, Kastelein, John J., Laskey, Rachel, Amarenco, Pierre, DeMicco, David A., and Waters, David D.
- Subjects
- *
BLOOD cholesterol measurement , *LOW density lipoproteins , *STATINS (Cardiovascular agents) , *CARDIOVASCULAR diseases , *PATIENTS , *PROGNOSIS , *ATHEROSCLEROSIS prevention , *ANTILIPEMIC agents , *ATHEROSCLEROSIS , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *MEDICAL protocols , *RESEARCH , *EVALUATION research , *RANDOMIZED controlled trials , *SIMVASTATIN , *DIAGNOSIS - Abstract
Background: The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the treatment of blood cholesterol recommends moderate- to high-intensity statins for patients with atherosclerotic cardiovascular disease but departs from the traditional treat-to-target approach. Whether percent low-density lipoprotein cholesterol (LDL-C) reduction or attained LDL-C levels add incremental prognostic value to statin dose is not known.Methods: Patients in the Treating to New Targets (TNT), Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL), and Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trials (patient-level data) randomized to a statin arm (atorvastatin 80 mg/10 mg or simvastatin 20 mg) were chosen. Patients were divided into groups based on attained LDL-C levels (≤70 vs >70 mg/dL) and percent LDL-C reduction (≥50% vs <50%). Primary outcome was major cardiovascular event defined as death due to coronary heart disease, nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke. Incremental prognostic value was assessed by using a forward conditional Cox proportional hazards model. Two models were tested: Model 1: Step 1 statin dose; Step 2 add attained LDL-C levels (continuous variable); Step 3 add percent LDL-C reduction (continuous variable). Model 2: Steps 2 and 3 were reversed.Results: Among 13,937 patients included in this study, percent LDL-C reduction added incremental prognostic value over both statin dose and attained LDL-C levels (global chi-square increased from 3.64 to 26.1 to 47.5; P <.0001). However, attained LDL-C level did not provide incremental prognostic value over statin dose and percent LDL-C reduction (global chi-square increased from 3.64 to 47.5 to 47.5; P <.0001 and .94, respectively). Among patients with attained LDL-C ≤70 mg/dL, those with percent LDL-C reduction of <50% had a significantly higher risk of primary outcome (hazard ratio [HR], 1.51; 95% confidence interval [CI], 1.16-1.97; P = .002) and stroke (HR, 2.07; 95% CI, 1.46-2.93; P <.0001) and a numerically higher risk of death (HR, 1.37; 95% CI, 0.98-1.90; P = .06) when compared with the group with percent LDL-C reduction of ≥50%.Conclusions: In patients with atherosclerotic cardiovascular disease, percent LDL-C reduction provides incremental prognostic value over statin dose and attained LDL-C levels. However, the attained LDL-C level does not provide additional prognostic value over statin dose and percent LDL-C reduction. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
48. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials.
- Author
-
Hsue, Priscilla Y, Bittner, Vera A, Betteridge, John, Fayyad, Rana, Laskey, Rachel, Wenger, Nanette K, and Waters, David D
- Published
- 2015
- Full Text
- View/download PDF
49. Impact of Female Sex on Lipid Lowering, Clinical CrassMark Outcomes, and Adverse Effects in Atorvastatin Trials.
- Author
-
Hsue, Priscilla Y., Bittner, Vera A., Betteridge, John, Fayyad, Rana, Laskey, Rachel, Wenger, Nanette K., and Waters, David D.
- Subjects
- *
ATORVASTATIN , *LIPIDS in the body , *CARDIOVASCULAR diseases , *PATIENTS , *DISEASES in women , *STROKE prevention , *CHOLESTEROL - Abstract
The aim of this study was to evaluate the effect of atorvastatin on lipid lowering, cardiovascular (CV) events, and adverse events in women compared with men in 6 clinical trials. In the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) trial (atorvastatin 80 mg vs simvastatin 20 to 40 mg), the Treating to New Targets (TNT) trial (atorvastatin 80 vs 10 mg), the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial (atorvastatin 80 mg vs placebo), and the Collaborative Atorvastatin Diabetes Study (CARDS), the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), and the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) (atorvastatin 10 mg vs placebo), lipid changes on treatment were compared between genders with studies grouped by dose. The association of on-study low-density lipoprotein (LDL) cholesterol and CV events by gender was evaluated in the combined studies and the impact of gender on adverse events in each study separately. Major CV events occurred in 3,083 of 30,000 men (10.3%) and 823 of 9,173 women (9.0%). Changes in lipids were similar in women and men. Major CV events were associated with gender-specific quintiles of on-treatment LDL cholesterol for women and men. In women, LDL cholesterol was a significant predictor of stroke, but not in men. Discontinuation rates due to adverse events were higher in women in 4 of 6 trials, but in only 1 trial was a significant treatment-gender interaction seen. Myalgia rates were slightly higher in women in both statin and placebo groups. In conclusion, the response of women to atorvastatin was similar to that of men, with slightly more discontinuations due to adverse events. Higher on-treatment LDL cholesterol was significantly associated with more CV events in both genders, but the association was stronger for stroke in women and for coronary heart disease death in men. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
50. Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers.
- Author
-
Arsenault, Benoit J., Barter, Philip, DeMicco, David A., Bao, Weihang, Preston, Gregory M., LaRosa, John C., Grundy, Scott M., Deedwania, Prakash, Greten, Heiner, Wenger, Nanette K., Shepherd, James, Waters, David D., Kastelein, John J. P., and null, null
- Subjects
- *
CARDIOVASCULAR agents , *CORONARY disease , *STATINS (Cardiovascular agents) , *RANDOMIZED controlled trials , *LIPIDS , *BIOMARKERS , *PATIENTS - Abstract
: Several plasma non-lipid biomarkers have been shown to predict major cardiovascular events (MCVEs) in population studies. Our objective was to investigate the relationship between lipid and non-lipid biomarkers levels achieved during statin therapy and the incidence of MCVEs in patients with stable coronary heart disease (CHD). We conducted a substudy of the TNT (Treating to New Targets) study, which was a randomized trial that compared the efficacy of high (80 mg) versus low (10 mg) dose atorvastatin for the secondary prevention of CHD. Fasting plasma levels of standard lipids and of 18 non-lipid biomarkers were obtained after an 8-week run-in period on atorvastatin 10 mg in 157 patients who experienced MCVEs during the 4.9 years of study follow-up and in 1349 controls. MCVE was defined as CHD death, nonfatal, non-procedure-related myocardial infarction, resuscitated cardiac arrest, and fatal or nonfatal stroke. After adjusting for age, sex and treatment arm, plasma levels of high-density lipoprotein (HDL) cholesterol, triglycerides, high-sensitivity C-reactive protein (hsCRP), insulin, neopterin, N-terminal pro-brain natriuretic peptide (BNP), lipoprotein(a) [Lp(a)], and the soluble receptor for advanced glycation end products (sRAGE) were predictive of recurrent MCVEs (P≤0.02 for each doubling of plasma concentration). However, no significant association was observed between the risk of recurrent MCVEs and plasma levels of low-density lipoprotein cholesterol, adiponectin, cystatin C, lipoprotein-associated phospholipase A2, monocyte chemotactic protein-1, matrix metalloproteinase-9, myeloperoxidase, osteopontin, soluble CD40 ligand, soluble intercellular adhesion molecule-1, or soluble vascular cell adhesion molecule-1. After further adjustment for diabetes, hypertension, smoking, and BMI, the relationship between hsCRP, insulin and MCVE were no longer significant, while the relationship between Lp(a), neopterin, NT-proBNP and sRAGE and MCVE remained statistically significant. In conclusion, in patients with CHD treated with atorvastatin, plasma levels of Lp(a), neopterin, NT-proBNP, and sRAGE are associated with the risk of recurrent MCVEs. Trial Registration: ClinicalTrials.gov . [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.